Results 31 to 40 of about 166,918 (340)
Clinical value of sentinel lymph node biopsy in patients with cutaneous and acral melanoma [PDF]
Zhongguo aizheng zazhi, 2022 Background and purpose: For cutaneous and acral malignant melanoma, sentinel lymph node biopsy (SLNB) is an effective tool to evaluate the situation of regional lymph node metastasis and to determine the pathological stage.
ZOU Zijian, SUN Wei, HU Tu, WANG Chunmeng, YAN Wangjun, LUO Zhiguo, LIU Xin, ZHONG Jingqin, LIN Xinyi, XU Yu, CHEN Yong
doaj +1 more source
Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones [PDF]
, 1997 Chromogranin A (CgA) is gaining acceptance as a serum marker of neuroendocrine tumors. Its specificity in differentiating between neuroendocrine and nonneuroendocrine tumors, its sensitivity to detect small tumors, and its clinical ...
Bouillon, R. (Roger) +8 more
core +4 more sources
MEN1 promotes ferroptosis by inhibiting mTOR-SCD1 axis in pancreatic neuroendocrine tumors
Acta Biochimica et Biophysica Sinica, 2022 Pancreatic neuroendocrine tumor (pNET) is the second most common malignant tumors of the pancreas. Multiple endocrine neoplasia 1 ( MEN1) is the most frequently mutated gene in pNETs and MEN1-encoded protein, menin, is a scaffold ...
Ye Zeng +16 more
doaj +1 more source
Discussing motherhood when the oncological prognosis is dire: ethical considerations for physicians
ESMO Open, 2020 Physicians are increasingly open to discussing and supporting pregnancy after cancer treatment. However, counselling patients who are seeking pregnancy despite advanced oncological disease and/or uncertain prognosis is still challenging. Two paradigmatic
Francesca Spada +3 more
doaj +1 more source
The novel mTOR inhibitor RAD001 (Everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells [PDF]
, 2007 Background/Aim: Tumors exhibiting constitutively activated PI(3) K/Akt/mTOR signaling are hypersensitive to mTOR inhibitors such as RAD001 (everolimus) which is presently being investigated in clinical phase II trials in various tumor entities, including
Albert JM +35 more
core +1 more source
Frontiers in Endocrinology, 2018 Background: Available neuroendocrine biomarkers are considered to have insufficient accuracy to discriminate patients with gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs) from healthy controls.
Mark J. C. van Treijen +15 more
doaj +1 more source
Frontiers in Surgery, 2022 BackgroundPancreatic neuroendocrine tumors (pNETs) and solid pseudopapillary tumors (SPTs) are two of the most common pancreatic neoplasms with different treatment procedures.
Hai-Feng Hu +37 more
doaj +1 more source
Treatment options for PNET liver metastases. a systematic review [PDF]
, 2018 Pancreatic neuroendocrine tumors (PNETs) are rare pancreatic neoplasms. About 40-80% of patients with PNET are metastatic at presentation, usually involving the liver (40-93%). Liver metastasis represents the most significant prognostic factor.
Aurello, Paolo +8 more
core +1 more source
Frontiers in Neuroendocrinology, 2001 Tumor markers used in the diagnosis and follow-up of patients with neuroendocrine tumors are in most instances not specific for a given tumor and circulate under normal conditions in the serum, making their use as an early diagnostic tool difficult (low sensitivity).
Lamberts, S.W.J. +2 more
openaire +2 more sources
Endocrine Connections, 2019 Introduction: Current monoanalyte biomarkers are ineffective in gastroenteropancreatic neuroendocrine tumors (GEP-NETs). NETest, a novel multianalyte signature, provides molecular information relevant to disease biology.
Anna Malczewska +9 more
doaj +1 more source